X
Very helpful. Thanks.
Description
@Point of Care™ With @sk Cognitive is a clinical decision-making mobile platform. Non-Small Cell Lung Cancer @Point of Care™ provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed—enabling better decisions, better outcomes, and better care.
With @sk Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Watson, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care.
Non-Small Cell Lung Cancer @Point of Care™ is designed to:
• Support discovery and practice change
• Provide relevant, evidence-based disease-specific medical content
• Improve patient outcomes at the point of care
Features:
• Continually updated Non-Small Cell Lung Cancer content
• Topics in diagnosis, treatment, and care management developed with expert physician authors
• Case studies, videos, and interviews
• Access to actionable patient-recorded data
• Detailed reference list with access to original sources
• Continuing medical education credit (CME/CE)
• Surveys and peer polling
• Patient education resources to share with patients
• BreakingMED™ news feed
Hide
Show More...
With @sk Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Watson, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care.
Non-Small Cell Lung Cancer @Point of Care™ is designed to:
• Support discovery and practice change
• Provide relevant, evidence-based disease-specific medical content
• Improve patient outcomes at the point of care
Features:
• Continually updated Non-Small Cell Lung Cancer content
• Topics in diagnosis, treatment, and care management developed with expert physician authors
• Case studies, videos, and interviews
• Access to actionable patient-recorded data
• Detailed reference list with access to original sources
• Continuing medical education credit (CME/CE)
• Surveys and peer polling
• Patient education resources to share with patients
• BreakingMED™ news feed
Screenshots
Non-Small Cell Lung Cancer FAQ
-
Is Non-Small Cell Lung Cancer free?
Yes, Non-Small Cell Lung Cancer is completely free and it doesn't have any in-app purchases or subscriptions.
-
Is Non-Small Cell Lung Cancer legit?
Not enough reviews to make a reliable assessment. The app needs more user feedback.
Thanks for the vote -
How much does Non-Small Cell Lung Cancer cost?
Non-Small Cell Lung Cancer is free.
-
What is Non-Small Cell Lung Cancer revenue?
To get estimated revenue of Non-Small Cell Lung Cancer app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.
User Rating
5 out of 5
1 ratings in France
5 star
1
4 star
0
3 star
0
2 star
0
1 star
0
Ratings History
Non-Small Cell Lung Cancer Reviews
Store Rankings
Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet
Non-Small Cell Lung Cancer Installs
Last 30 days
Non-Small Cell Lung Cancer Revenue
Last 30 daysNon-Small Cell Lung Cancer Revenue and Downloads
Gain valuable insights into Non-Small Cell Lung Cancer performance with our analytics.
Sign up now to access downloads, revenue, and more.
Sign up now to access downloads, revenue, and more.
App Info
- Category
- Medical
- Publisher
- @Point of Care
- Languages
- English
- Recent release
- 12.2.7 (6 months ago )
- Released on
- Mar 2, 2012 (12 years ago )
- Also available in
- United States , Philippines , Austria , Kuwait , Taiwan , India , France , Canada , Mexico , United Kingdom , China , Romania , Denmark , Greece , Netherlands , Pakistan , Nigeria , Malaysia , Lebanon , Kazakhstan , South Korea , Norway , New Zealand , Peru , Ireland , Poland , Portugal , Saudi Arabia , Sweden , Singapore , Thailand , Türkiye , Vietnam , South Africa , Dominican Republic , Argentina , Australia , Azerbaijan , Belgium , Bahrain , Brazil , Belarus , Switzerland , Chile , Colombia , Czechia , Germany , Japan , Algeria , Ecuador , Egypt , Spain , Finland , Hong Kong SAR China , Hungary , Indonesia , United Arab Emirates , Israel , Italy
- Last Updated
- 1 week ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.